Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL791977 | 0.81 | TAAR1 (0.67) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL30080050 | 0.77 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL723511 | 0.77 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL21875849 | 0.77 | TAAR1 (0.51) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL28209116 | 0.76 | CA1 (0.46) | IDO1 | |
| SCHEMBL17230492 | 0.76 | TAAR1 (0.59) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL21875878 | 0.75 | TAAR1 (0.58) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL8699099 | 0.75 | CHRM2 (0.63) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL6569361 | 0.74 | MTNR1A (0.53) | TAAR1CHRM2CHRM1CHRM3MTNR1A | |
| SCHEMBL833882 | 0.74 | TAAR1 (0.67) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3647315-B9 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | VIVAVISION BIOTECH LTD (CN) | 2025-06-04 | — | — | EP | disclosed |
| EP-3647315-B1 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | VIVAVISION BIOTECH LTD (CN) | 2024-11-20 | — | — | EP | disclosed |
| US-11325929-B2 | Phosphorus-containing compound and preparation and use thereof | VIVAVISIONSHANGHAILTD (CN) | 2022-05-10 | — | — | US | disclosed |
| EP-3647315-A1 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | Vivavisionshanghailtd (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-20200131206-A1 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | VIVAVISIONSHANGHAILTD (CN) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325929-B2 | Phosphorus-containing compound and preparation and use thereof | INPP5D, CXCL12, INPPL1 | TAAR1 4070/4885CHRM2 2637/4885CHRM1 3364/4885 |
| US-20200131206-A1 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | INPP5D, CXCL12, INPPL1 | TAAR1 4070/4885CHRM2 2637/4885CHRM1 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.